Building world-first outcomes can be as transformative as it is tumultuous at times. Yet, I can boldly say that Spiral is a global leader in novel clinical trial innovation and, more specifically, in randomisation.

We’re redefining the parameters of randomisation in all its forms and building a future-ready platform with Blazor’s next-gen development framework.

This means more intuitive interfaces streamlining workflows, improving time-critical decision-making, and enhancing global patient care. 

It enables our users, many of whom work on the frontline in ICU environments, to focus on saving lives rather than navigating cumbersome technology.

It’s bold. It’s brave. And it’s trailblazing!

Randomisation is our superpower. True innovation can be challenging, but I always find it to be groundbreaking.

With everything we do, partnering early and co-designing throughout is critical to the result. We’re constantly managing the need for speed with the critical nature of quality, particularly in eligibility and randomisation, where 110% is a non-negotiable.

Building trial architectures for the future involves navigating complexities and staying committed to our vision and values. Our expertise in designing adaptive databases is key to managing these complexities.

Navigating transformation while scaling to meet demand requires solid partnerships and exceptional people. In fact, they mean everything to me!

In New Zealand, we have a guiding principle called kaitiakitanga, or guardianship. This principle shapes our approach to building and maintaining robust, scalable, novel trial innovation.

As we continue to push the boundaries of what’s possible, we ask only one thing of our clients: to push the boundaries alongside us.

Audrey Shearer, CEO & Founder, Spiral Software